BACKGROUND: Cocaine use is common in opioid-dependent HIV-infected patients, but its impact on treatment outcomes in these patients receiving buprenorphine/naloxone is not known. METHODS: We conducted a prospective study in 299 patients receiving buprenorphine/naloxone who provided baseline cocaine data and a subset of 266 patients who remained in treatment for greater than or equal to one quarter. Assessments were conducted at baseline and quarterly for 1 year. We evaluated the association between baseline and in-treatment cocaine use on buprenorphine/naloxone retention, illicit opioid use, antiretroviral adherence, CD4 counts, HIV RNA, and risk behaviors. RESULTS: Sixty-six percent (197 of 299) of patients reported baseline cocaine use and 65% (173 of 266) of patients with follow-up data reported in-treatment cocaine use. Baseline and in-treatment cocaine use did not impact buprenorphine/naloxone retention, antiretroviral adherence, CD4 lymphocytes, or HIV risk behaviors. However, baseline cocaine use was associated with a 14.8 (95% confidence interval [CI], 9.0-24.2) times greater likelihood of subsequent cocaine use (95% CI, 9.0-24.2), a 1.4 (95% CI, 1.02-2.00) times greater likelihood of subsequent opioid use, and higher log10 HIV RNA (P < 0.016) over time. In-treatment cocaine use was associated with a 1.4 (95% CI, 1.01-2.00) times greater likelihood of concurrent opioid use. CONCLUSIONS: Given cocaine use negatively impacts opioid and HIV treatment outcomes, interventions to address cocaine use in HIV-infected patients receiving buprenorphine/naloxone treatment are warranted.
BACKGROUND:Cocaine use is common in opioid-dependent HIV-infectedpatients, but its impact on treatment outcomes in these patients receiving buprenorphine/naloxone is not known. METHODS: We conducted a prospective study in 299 patients receiving buprenorphine/naloxone who provided baseline cocaine data and a subset of 266 patients who remained in treatment for greater than or equal to one quarter. Assessments were conducted at baseline and quarterly for 1 year. We evaluated the association between baseline and in-treatment cocaine use on buprenorphine/naloxone retention, illicit opioid use, antiretroviral adherence, CD4 counts, HIV RNA, and risk behaviors. RESULTS: Sixty-six percent (197 of 299) of patients reported baseline cocaine use and 65% (173 of 266) of patients with follow-up data reported in-treatment cocaine use. Baseline and in-treatment cocaine use did not impact buprenorphine/naloxone retention, antiretroviral adherence, CD4 lymphocytes, or HIV risk behaviors. However, baseline cocaine use was associated with a 14.8 (95% confidence interval [CI], 9.0-24.2) times greater likelihood of subsequent cocaine use (95% CI, 9.0-24.2), a 1.4 (95% CI, 1.02-2.00) times greater likelihood of subsequent opioid use, and higher log10 HIV RNA (P < 0.016) over time. In-treatment cocaine use was associated with a 1.4 (95% CI, 1.01-2.00) times greater likelihood of concurrent opioid use. CONCLUSIONS: Given cocaine use negatively impacts opioid and HIV treatment outcomes, interventions to address cocaine use in HIV-infectedpatients receiving buprenorphine/naloxone treatment are warranted.
Authors: Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: H E Cejtin; E Komaroff; L S Massad; A Korn; J B Schmidt; D Eisenberger-Matiyahu; E Stier Journal: J Acquir Immune Defic Syndr Date: 1999-11-01 Impact factor: 3.731
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Nancy L Sohler; Mitchell D Wong; William E Cunningham; Howard Cabral; Mari-Lynn Drainoni; Chinazo O Cunningham Journal: AIDS Patient Care STDS Date: 2007 Impact factor: 5.078
Authors: Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Brent A Moore; Marc I Rosen; Yan Wang; Jie Shen; Karen Ablondi; Anna Sullivan; Mario Guerrero; Lisa Siqueiros; Eric S Daar; Honghu Liu Journal: AIDS Behav Date: 2015-06
Authors: M Eugenia Socías; Evan Wood; Will Small; Huiru Dong; Jean Shoveller; Thomas Kerr; Julio Montaner; M-J Milloy Journal: Drug Alcohol Depend Date: 2016-09-20 Impact factor: 4.492
Authors: Chinazo O Cunningham; Angela Giovanniello; Hillary V Kunins; Robert J Roose; Aaron D Fox; Nancy L Sohler Journal: Am J Addict Date: 2013 Jul-Aug
Authors: Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Sharon M Kelly; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz Journal: J Subst Abuse Treat Date: 2013-04-05
Authors: Sarah M Bagley; Debbie M Cheng; Michael Winter; Daniel P Alford; Colleen LaBelle; Alexander Y Walley; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2018-09-25 Impact factor: 4.492